cannabidiol

FibroBiologics is expanding its intellectual property strategy for degenerative disc disease with an Australian patent acceptance covering cannabidiol as an adjuvant to fibroblast-based regenerative therapy, although clinical validation remains the critical next step. Representative image.

Pharma & Biotech

What FibroBiologics’ Australian cannabidiol patent means for its degenerative disc disease pipeline

by Pallavi Madhiraju
August 22, 2026
0 Comments

FibroBiologics expands its disc disease IP in Australia, but clinical validation and funding remain the bigger tests for its regenerative strategy.

Read More